Brush Biopsy — Transepithelial Sample Collection Template

Brush biopsy - transepithelial sample collection.

RMH: Medical history reviewed/updates

Site: Site/tooth area
Lesion description: Lesion description
Size: Size
Duration: Duration

Procedure:
Brush biopsy performed.
Cells collected from lesion.
Sample placed on slide.
Sent to laboratory: Laboratory/specimen details

Complications: None or describe.

Patient tolerance: Tolerance/response.

No post-op restrictions.

Results to be discussed at follow-up.

NV: Next visit

Biopsy code support: Incisional/excisional/cell collection
Clinical appearance: Color, borders, ulceration, induration, symptoms
Pre-op photo/size/location: Photo taken; lesion size and anatomical location
Removal method/pathology: Method of tissue removal; lab sent; pathology result follow-up plan

Documentation requirements

Brush biopsy is a low-morbidity, high-stakes procedure: the chart and the cytology report together drive whether a clinically uncertain lesion gets escalated to definitive biopsy or watched. Documentation has to make the lesion, the technique, the sample handling, and the closed-loop follow-up plan unambiguous to a third-party reviewer. A defensible D7288 note must contain:

• Date of service and start/stop time — useful when cross-coding to medical and when supporting any medical-necessity narrative.
• Medical and dental history reviewed — including tobacco (pack-years), alcohol (drinks/week), HPV history, prior oral cancer, prior head/neck radiation, immunosuppression, and any anti-resorptive therapy. Risk factors are what justify sampling a lesion that visually looks low-grade; absent risk-factor documentation, reviewers commonly question medical necessity.
• Vitals — pre-op BP and pulse on operative or sampling visits per most state board expectations. Brush biopsy itself rarely requires post-op vitals.
• Chief complaint and history of present illness — when the lesion was first noticed, any change in size / color / symptoms over time, prior treatment attempted (irritation source removal, antifungal, observation), and whether the lesion has recurred.
• Site / anatomical location — specific named site (e.g., "left buccal mucosa at the occlusal plane, opposite #14"), not a generic region. Anatomical precision is essential for re-sampling, escalation to incisional biopsy, or matching subsequent photographs to the same lesion.
• Lesion description — objective findings — color, size in millimeters in two dimensions, shape, borders (well-defined vs. ill-defined), surface (smooth, granular, papillary, ulcerated), consistency (soft vs. firm — induration is a red flag that should push to D7286 instead of D7288), mobility, fixation, and surrounding mucosa. Patient-specific findings, not a default-normal template line.
• Duration — how long the lesion has been present, with attention to lesions persisting >14 days. A lesion that has been present for many months in a low-risk patient is a typical D7288 indication; a 2-week persistent lesion in a heavy smoker is a typical D7286 indication.
• Risk factors specific to this patient — tobacco pack-years, alcohol drinks/week, HPV history, prior oral cancer, immunosuppression, head/neck radiation. These belong in the brush biopsy note even if they are also in the medical history; together with the lesion description, they justify the choice of D7288 vs. D7286.
• Pre-op intraoral photograph(s) — at least one photograph documenting the lesion, ideally with a millimeter ruler in frame and one wide-field view for anatomical context. AAOMS, AAOMP, and most malpractice carriers consider a pre-op photo standard of care for any oral lesion sampling, and reviewers increasingly cite missing photos as a documentation gap.
• Clinical impression / differential — the clinician's working differential before cytology (e.g., "differential includes frictional keratosis vs. mild dysplasia vs. lichenoid mucositis"). A brush biopsy is most defensible when the chart shows an articulated differential that the cytology result can resolve.
• Why D7288 instead of D7286 — a one-sentence rationale linking the lesion characteristics and risk profile to the choice of brush biopsy over scalpel biopsy (e.g., "small, non-indurated, well-defined leukoplakia in a non-smoker; brush biopsy chosen for triage rather than incisional biopsy"). This is the single most useful sentence on a D7288 note for both audits and malpractice.
• Consent / PARQ — signed or verbally obtained. PARQ should cover the rationale (cytologic triage of a suspicious lesion), alternatives (continued observation with photo monitoring, definitive incisional biopsy under D7286, OMFS / oral medicine referral), risks (minor bleeding, transient soreness, non-diagnostic specimen, sampling error, false negative on a truly dysplastic lesion, need for definitive biopsy if cytology is atypical or positive), and the explicit understanding that a cytology report will be issued and reviewed with the patient.
• Sampling technique — explicit confirmation that the procedure is transepithelial brush biopsy. Document the brand / kit (OralCDx BrushTest is most common), the number of brush rotations applied, and that pinpoint bleeding was achieved on the lesion surface (the operator's confirmation that the brush penetrated to the basal layer). This sentence is what differentiates D7288 from D7287 in the chart.
• Anesthesia, if any — most brush biopsies require no anesthesia. If topical benzocaine or local lidocaine was used, document agent, concentration, and amount; otherwise write "none — sampling tolerated without anesthesia."
• Specimen handling — cells transferred to slide(s), fixative used (alcohol spray or jar per the receiving lab; OralCDx kits include a pre-supplied fixative), labeled with patient name, DOB, site, and date. Cytology specimens are not placed in formalin — formalin denatures cytologic stains and ruins the specimen; this is a frequent documentation error when the office is more familiar with D7286.
• Cytology laboratory and requisition — name of the laboratory (OralCDx CDx Diagnostics is the canonical brush biopsy lab; some practices use regional cytopathology labs), requisition number when available, and what was sent on the requisition (clinical history, site, lesion description, clinical impression, risk factors, clinician contact information).
• Result-disclosure plan — explicit documentation of how the result will be communicated (phone, patient portal, in-person follow-up), the expected turnaround (typically 7-10 business days for OralCDx), and the next-step contingency depending on the result: a "negative" result supports observation with photo monitoring at a defined interval; an "atypical" or "positive" result mandates definitive incisional biopsy (D7286) or OMFS / oral medicine referral. The plan to file the cytology report in the chart upon receipt and notify the patient regardless of result is itself part of the record.
• Complications — explicit "None" or describe (excessive bleeding, syncope, vasovagal). Brush biopsy complications are rare; affirmatively document the absence rather than leaving the line silent.
• Patient tolerance and response — tolerated well, mild discomfort with rotation, no vasovagal symptoms.
• Post-op instructions — minimal for D7288; avoid abrasive food at the sample site for the rest of the day, watch for unexpected bleeding or pain, normal hygiene resumed tomorrow. Counsel on tobacco / alcohol cessation when applicable.
• Next visit — concrete date for cytology result review and clinical re-exam (typically 7-10 business days after sampling). Document the contingency plan if cytology is atypical or positive (immediate scheduling of D7286, OMFS referral).
• Provider signature and assistant initials — required.

Two phrases that defuse the most common audit and malpractice questions on a D7288 note: an explicit "transepithelial brush biopsy with OralCDx BrushTest; pinpoint bleeding achieved confirming basal-layer sampling; specimen sent to CDx Diagnostics on [date]" line, and an explicit "result will be reviewed with patient at [date]; if atypical or positive, escalation to D7286 incisional biopsy will be performed at the next visit" line. Together they document the closed-loop responsibility that any biopsy code carries.

Common denial reasons

D7288 has its own denial pattern, distinct from incisional biopsy and from extraction codes. The most frequent reasons it is denied, downgraded, or recouped:

• Carrier classifies brush biopsy as experimental / investigational — some payer clinical policies still treat oral brush biopsy as adjunctive screening rather than a diagnostic procedure and exclude it. Appeals citing the lesion's clinical features, the documented differential, and the diagnostic uncertainty that justified sampling sometimes overturn these denials.
• Code-descriptor mismatch in the chart — note describes a scrape, swab, or simple brush of the lesion surface but billed as D7288. Reviewer recodes to D7287 (typically a lower allowable) or denies for "service not consistent with documented procedure." Brush biopsy must be transepithelial, with pinpoint bleeding documented as evidence the brush penetrated to the basal layer.
• D7288 billed when D7287 was performed — surface-only cell collection (scrape, swab, non-transepithelial brush) belongs to D7287. If your kit was a generic cytobrush rather than an OralCDx-style stiff transepithelial brush, the correct code is D7287.
• D7288 billed alongside D7286 on the same lesion same DOS — bundled by most carriers as inclusive; only the definitive biopsy pays. Document separate sites if both are clinically warranted.
• Submitted to dental insurance only when plan does not cover — many dental plans do not list D7288 as a covered benefit; the carrier denies for benefit, not documentation. Cross-code to medical CPT when applicable.
• No clinical photo or measurement documented — payers that require image documentation for biopsy/cytology codes will deny without it. AAOMS, AAOMP, and most malpractice carriers consider a pre-op photo standard of care.
• Default-normal lesion description — copy-paste "white plaque, asymptomatic" with no measurements, borders, duration, or risk-factor context on every brush biopsy claim looks fabricated and supports a recoupment finding.
• No clinical impression / differential documented — the chart should explain why a brush biopsy was indicated and what diagnoses the cytology was meant to resolve. Absent a differential, reviewers question medical necessity.
• No rationale for D7288 instead of D7286 — when the lesion description reads as high-suspicion (red-white plaque, induration, lateral tongue site, heavy smoker) but a brush biopsy was performed, reviewers question whether a definitive biopsy was inappropriately deferred. A one-sentence rationale linking the lesion characteristics to the choice of brush biopsy resolves this.
• Specimen-handling errors — cells placed in formalin (denatures cytologic stains), unlabeled slide, missing requisition, wrong fixative for the receiving lab. The cytology report comes back as "non-diagnostic" or "specimen unsatisfactory," undermining both the medical-necessity claim and the standard of care.
• Result not reconciled in the chart — cytology was sent but no report is filed, no patient was notified, and no follow-up was scheduled. This is the highest-malpractice-exposure failure mode for D7288 — a missed atypical or positive cytology on an oral cancer screening test is a frequent malpractice claim. Several state OIG and dental board reports cite "specimen sent without follow-up" as a quality-of-care finding.
• Repeat D7288 on the same lesion — re-brushing a previously atypical or positive lesion instead of escalating to D7286 is denied as not medically necessary and is below the standard of care.
• Brush biopsy of visually normal mucosa as routine screening — D7288 is intended for clinically suspicious lesions; brushing visually normal mucosa as a stand-alone cancer screen is not a recognized indication and most carriers will not cover it.
• PARQ missing the malignancy / escalation contingency — consent that does not include the possibility of an atypical or positive result requiring definitive biopsy supports a malpractice claim if the patient later presents with a missed lesion.
• Submitted without diagnosis code (medical cross) — when cross-coding to medical, missing or non-specific ICD-10 (e.g., R68.89 unspecified instead of K13.21 leukoplakia) triggers automated medical denials.

Related templates